This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB01295/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01295/identifier/chemspider/
n11http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB01295/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01295/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01295/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01295/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01295
rdf:type
n3:Drug
n3:description
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
n3:generalReferences
# Vaughan Williams EM: Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2888789
n3:group
approved
n3:indication
For the treatment of angina pectoris and hypertension.
owl:sameAs
n10:DB01295 n11:DB01295
dcterms:title
Bevantolol
adms:identifier
n8:PA164743236 n13:238698 n14:2282 n15:46506014 n16:DB01295 n19:2372
n3:mechanismOfAction
Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure.
n3:synonym
1-(3,4-Dimethoxyphenethylamino)-3-(m-tolyloxy)-2-propanol Bevantololum 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol 1-(3,4-Dimethoxyphenethylamino)-3-m-tolyloxy-propan-2-ol (+-)-Bevantolol 1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol
n3:synthesisReference
Yutaka Nomura, "Process for preparation of bevantolol hydrochloride." U.S. Patent US5382689, issued December, 1974.
n17:hasConcept
n18:M0075645
n3:IUPAC-Name
n4:271B63B5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B63BB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B63BA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B63B7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B63B8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B63B9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B63B3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B63CC-363D-11E5-9242-09173F13E4C5 n4:271B63B1-363D-11E5-9242-09173F13E4C5 n4:271B63B4-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B63B2-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:C07AB06
n3:H-Bond-Acceptor-Count
n4:271B63C1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B63C2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B63BC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B63BD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B63BF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B63BE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B63C0-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59170-23-9
n3:category
n3:Bioavailability
n4:271B63C7-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B63C9-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B63CA-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B63CB-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B63C6-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B63C5-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B63C8-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B63B6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B63C3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B63C4-363D-11E5-9242-09173F13E4C5